Supplementary Online Content


eTable. Number of Delirium Symptom Score (NuDESC items 2, 3, 4) Observations Prior to Each Dose by Group

eFigure 1. MDAS Scores (Delirium Severity) Over the Study Period by Study Arm

eFigure 2. Mean Dose Administered During Study period by Study Arm for the 2 Age Groups

This supplementary material has been provided by the authors to give readers additional information about their work.
**eTable. Number of Delirium Symptom Score (NuDESC items 2, 3, 4)**

Observations Prior to Each Dose by Group

<table>
<thead>
<tr>
<th></th>
<th>Eligibility (mean, SD)</th>
<th>before Dose 1 (Baseline)</th>
<th>Before dose 2</th>
<th>Before dose 3</th>
<th>Before dose 4</th>
<th>Before dose 5</th>
<th>Before dose 6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Placebo</strong></td>
<td>82 (2.54, 1.43)</td>
<td>78 (2.10, 1.28)</td>
<td>72 (1.31, 1.37)</td>
<td>68 (0.96, 1.15)</td>
<td>68 (0.89, 1.08)</td>
<td>64 (0.70, 1.00)</td>
<td>64 (0.71, 1.25)</td>
</tr>
<tr>
<td><strong>Risperidone</strong></td>
<td>80 (2.54, 1.23)</td>
<td>78 (2.25, 1.31)</td>
<td>67 (1.93, 1.39)</td>
<td>61 (1.72, 1.47)</td>
<td>59 (1.64, 1.45)</td>
<td>47 (1.55, 1.65)</td>
<td>46 (1.26, 1.37)</td>
</tr>
<tr>
<td><strong>Haloperidol</strong></td>
<td>81 (2.60, 1.48)</td>
<td>79 (2.20, 1.34)</td>
<td>73 (1.60, 1.50)</td>
<td>65 (1.30, 1.27)</td>
<td>66 (1.20, 1.32)</td>
<td>59 (1.19, 1.18)</td>
<td>59 (1.29, 1.33)</td>
</tr>
</tbody>
</table>
eFigure 1. MDAS Scores (Delirium Severity) Over the Study Period by Study Arm

© 2016 American Medical Association. All rights reserved.
eFigure 2. Mean Dose Administered During Study period by Study Arm for the 2 Age Groups
A  Patients older than 65 years

B  Patients 65 years or younger